Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Dermatology

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 148 articles:
HTML format
Text format



Single Articles


    November 2017
  1. FRICK MA, Vachani CC, Bach C, Hampshire MK, et al
    Survivorship and the chronic cancer patient: Patterns in treatment-related effects, follow-up care, and use of survivorship care plans.
    Cancer. 2017;123:4268-4276.
    PubMed     Text format     Abstract available


    October 2017
  2. MCWILLIAMS RR, Allred JB, Slostad JA, Katipamula R, et al
    NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab +/- everolimus for metastatic melanoma.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31072.
    PubMed     Text format     Abstract available


  3. AMIT M, Tam S, Abdelmeguid AS, Roberts DB, et al
    Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31083.
    PubMed     Text format     Abstract available


  4. CHAD-FRIEDMAN E, Coleman S, Traeger LN, Pirl WF, et al
    Psychological distress associated with cancer screening: A systematic review.
    Cancer. 2017;123:3882-3894.
    PubMed     Text format     Abstract available


  5. SLOOT S, Chen YA, Zhao X, Weber JL, et al
    Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
    Cancer. 2017 Oct 12. doi: 10.1002/cncr.30946.
    PubMed     Text format     Abstract available


  6. ARLEO EK, Hendrick RE, Helvie MA, Sickles EA, et al
    Comparison of recommendations for screening mammography using CISNET models.
    Cancer. 2017;123:3673-3680.
    PubMed     Text format     Abstract available


    September 2017
  7. NGUYEN KH, Pasick RJ, Stewart SL, Kerlikowske K, et al
    Disparities in abnormal mammogram follow-up time for Asian women compared with non-Hispanic white women and between Asian ethnic groups.
    Cancer. 2017;123:3468-3475.
    PubMed     Text format     Abstract available


  8. KAROL SE, Yang W, Smith C, Cheng C, et al
    Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine.
    Cancer. 2017;123:3602-3608.
    PubMed     Text format     Abstract available


  9. BENCI JL, Minn AJ, Vachani CC, Bach C, et al
    Survivorship care planning in skin cancer: An unbiased statistical approach to identifying patterns of care-plan use.
    Cancer. 2017 Sep 8. doi: 10.1002/cncr.30985.
    PubMed     Text format     Abstract available


    August 2017
  10. SENNERSTAM RB, Franzen BSH, Wiksell HOT, Auer GU, et al
    Core-needle biopsy of breast cancer is associated with a higher rate of distant metastases 5 to 15 years after diagnosis than FNA biopsy.
    Cancer. 2017 Aug 24. doi: 10.1002/cncy.21909.
    PubMed     Text format     Abstract available


  11. MASTELLARO MJ, Seidinger AL, Kang G, Abrahao R, et al
    Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: Insights from the study of 55 families of children with adrenocortical tumors.
    Cancer. 2017;123:3150-3158.
    PubMed     Text format     Abstract available


  12. MARMOR S, Hui JYC, Huang JL, Kizy S, et al
    Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Cancer. 2017;123:3015-3021.
    PubMed     Text format     Abstract available


  13. JAGAI JS, Messer LC, Rappazzo KM, Gray CL, et al
    County-level cumulative environmental quality associated with cancer incidence.
    Cancer. 2017;123:2901-2908.
    PubMed     Text format     Abstract available


  14. VAZ-LUIS I, O'Neill A, Sepucha K, Miller KD, et al
    Survival benefit needed to undergo chemotherapy: Patient and physician preferences.
    Cancer. 2017;123:2821-2828.
    PubMed     Text format     Abstract available


    July 2017
  15. POWIS M, Sutradhar R, Gonzalez A, Enright KA, et al
    Establishing achievable benchmarks for quality improvement in systemic therapy for early-stage breast cancer.
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30804.
    PubMed     Text format     Abstract available


  16. MARINA NM, Liu Q, Donaldson SS, Sklar CA, et al
    Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study.
    Cancer. 2017;123:2551-2560.
    PubMed     Text format     Abstract available


  17. KOPP RP, Stratton KL, Glogowski E, Schrader KA, et al
    Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
    Cancer. 2017;123:2452-2458.
    PubMed     Text format     Abstract available


    June 2017
  18. TARAZI WW, Bradley CJ, Bear HD, Harless DW, et al
    Impact of Medicaid disenrollment in Tennessee on breast cancer stage at diagnosis and treatment.
    Cancer. 2017 Jun 26. doi: 10.1002/cncr.30771.
    PubMed     Text format     Abstract available


  19. WALLNER LP, Li Y, McLeod MC, Hamilton AS, et al
    Decision-support networks of women newly diagnosed with breast cancer.
    Cancer. 2017 Jun 22. doi: 10.1002/cncr.30848.
    PubMed     Text format     Abstract available


  20. ABRAHAMS HJG, Gielissen MFM, Donders RRT, Goedendorp MM, et al
    The efficacy of Internet-based cognitive behavioral therapy for severely fatigued survivors of breast cancer compared with care as usual: A randomized controlled trial.
    Cancer. 2017 Jun 16. doi: 10.1002/cncr.30815.
    PubMed     Text format     Abstract available


  21. BERRY V, Basson L, Bogart E, Mir O, et al
    REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis.
    Cancer. 2017;123:2294-2302.
    PubMed     Text format     Abstract available


  22. SZCZEPANIAK SLOANE RA, Gopalakrishnan V, Reddy SM, Zhang X, et al
    Interaction of molecular alterations with immune response in melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  23. BYRNE EH, Fisher DE
    Immune and molecular correlates in melanoma treated with immune checkpoint blockade.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  24. WESTPHAL D, Glitza Oliva IC, Niessner H
    Molecular insights into melanoma brain metastases.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  25. LIM SY, Menzies AM, Rizos H
    Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  26. PEREZ-GUIJARRO E, Day CP, Merlino G, Zaidi MR, et al
    Genetically engineered mouse models of melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  27. REDDY BY, Miller DM, Tsao H
    Somatic driver mutations in melanoma.
    Cancer. 2017;123.
    PubMed     Text format     Abstract available


  28. PRINSLOO S, Novy D, Driver L, Lyle R, et al
    Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study.
    Cancer. 2017;123:1989-1997.
    PubMed     Text format     Abstract available


    May 2017
  29. KOROUKIAN SM, Bakaki PM, Htoo PT, Han X, et al
    The Breast and Cervical Cancer Early Detection Program, Medicaid, and breast cancer outcomes among Ohio's underserved women.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30720.
    PubMed     Text format     Abstract available


  30. BROWNE JP, Jeevan R, Gulliver-Clarke C, Pereira J, et al
    The association between complications and quality of life after mastectomy and breast reconstruction for breast cancer.
    Cancer. 2017 May 17. doi: 10.1002/cncr.30788.
    PubMed     Text format     Abstract available


  31. HENRY NL, Braun TM, Ali HY, Munir K, et al
    Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry.
    Cancer. 2017;123:948-956.
    PubMed     Text format     Abstract available


  32. ZHAO H, Hei N, Wu Y, Chan W, et al
    Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ.
    Cancer. 2017;123:940-947.
    PubMed     Text format     Abstract available


  33. LONG ROCHE KC, Abu-Rustum NR, Nourmoussavi M, Zivanovic O, et al
    Risk-reducing salpingectomy: Let us be opportunistic.
    Cancer. 2017;123:1714-1720.
    PubMed     Text format     Abstract available


  34. FRICK MA, Vachani CC, Hampshire MK, Bach C, et al
    Survivorship after lower gastrointestinal cancer: Patient-reported outcomes and planning for care.
    Cancer. 2017;123:1860-1868.
    PubMed     Text format     Abstract available


  35. GOEPFERT RP, Hutcheson KA, Lewin JS, Desai NG, et al
    Complications, hospital length of stay, and readmission after total laryngectomy.
    Cancer. 2017;123:1760-1767.
    PubMed     Text format     Abstract available


  36. GHAZAWI FM, Netchiporouk E, Rahme E, Tsang M, et al
    Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy.
    Cancer. 2017 May 10. doi: 10.1002/cncr.30758.
    PubMed     Text format     Abstract available


  37. LIPTON A, Chapman JW, Leitzel K, Garg A, et al
    Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
    Cancer. 2017 May 2. doi: 10.1002/cncr.30682.
    PubMed     Text format     Abstract available


  38. COOPER GS, Kou TD, Dor A, Koroukian SM, et al
    Cancer preventive services, socioeconomic status, and the Affordable Care Act.
    Cancer. 2017;123:1585-1589.
    PubMed     Text format     Abstract available


  39. SHIELD PW, Frost F, Finnimore JL, Wright RG, et al
    External quality assurance in nongynecologic cytology: The Australasian experience.
    Cancer. 2017;125:349-361.
    PubMed     Text format     Abstract available


    April 2017
  40. HSU CD, Wang X, Habif DV Jr, Ma CX, et al
    Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in US women 18 to 64 years old.
    Cancer. 2017 Apr 25. doi: 10.1002/cncr.30722.
    PubMed     Text format     Abstract available


  41. KATZ SJ, Wallner LP, Abrahamse PH, Janz NK, et al
    Treatment experiences of Latinas after diagnosis of breast cancer.
    Cancer. 2017 Apr 11. doi: 10.1002/cncr.30702.
    PubMed     Text format     Abstract available


  42. LIANG X, Margolis KL, Hendryx M, Reeves K, et al
    Effect of depression before breast cancer diagnosis on mortality among postmenopausal women.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30688.
    PubMed     Text format     Abstract available


  43. CASSIDY RJ, Liu Y, Kahn ST, Jegadeesh NK, et al
    The role of postmastectomy radiotherapy in women with pathologic T3N0M0 breast cancer.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30675.
    PubMed     Text format     Abstract available


  44. KROENKE CH, Michael YL, Poole EM, Kwan ML, et al
    Postdiagnosis social networks and breast cancer mortality in the After Breast Cancer Pooling Project.
    Cancer. 2017;123:1228-1237.
    PubMed     Text format     Abstract available


    March 2017
  45. KALINSKY K, Lee S, Rubin KM, Lawrence DP, et al
    A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
    Cancer. 2017 Mar 23. doi: 10.1002/cncr.30663.
    PubMed     Text format     Abstract available


  46. MAMTANI A, Patil S, Stempel MM, Morrow M, et al
    Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
    Cancer. 2017 Mar 23. doi: 10.1002/cncr.30658.
    PubMed     Text format     Abstract available


  47. HENRY NL, Braun TM, Breslin TM, Gorski DH, et al
    Variation in the use of advanced imaging at the time of breast cancer diagnosis in a statewide registry.
    Cancer. 2017 Mar 16. doi: 10.1002/cncr.30674.
    PubMed     Text format     Abstract available


  48. CESPEDES FELICIANO EM, Kwan ML, Kushi LH, Chen WY, et al
    Body mass index, PAM50 subtype, recurrence and survival among patients with nonmetastatic breast cancer.
    Cancer. 2017 Mar 13. doi: 10.1002/cncr.30637.
    PubMed     Text format     Abstract available


  49. LIN HY, Bedrosian I, Babiera GV, Shaitelman SF, et al
    Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer.
    Cancer. 2017 Mar 13. doi: 10.1002/cncr.30660.
    PubMed     Text format     Abstract available


  50. LUCAS AR, Levine BJ, Avis NE
    Posttreatment trajectories of physical activity in breast cancer survivors.
    Cancer. 2017 Mar 8. doi: 10.1002/cncr.30641.
    PubMed     Text format     Abstract available


  51. FU J, Wu L, Jiang M, Li D, et al
    Real-world impact of non-breast cancer-specific death on overall survival in resectable breast cancer.
    Cancer. 2017 Mar 7. doi: 10.1002/cncr.30617.
    PubMed     Text format     Abstract available


  52. ZHANG FF, Haslam DE, Terry MB, Knight JA, et al
    Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry.
    Cancer. 2017 Mar 6. doi: 10.1002/cncr.30615.
    PubMed     Text format     Abstract available


  53. KEAM B, Kim MK, Choi Y, Choi SJ, et al
    Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles.
    Cancer. 2017;123:841-848.
    PubMed     Text format     Abstract available


    February 2017
  54. WONG SM, Stout NK, Punglia RS, Prakash I, et al
    Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis.
    Cancer. 2017 Feb 21. doi: 10.1002/cncr.30644.
    PubMed     Text format     Abstract available



  55. Some Europeans with melanoma lack access to new, lifesaving drugs.
    Cancer. 2017;123:543-544.
    PubMed     Text format    


  56. YEE MK, Sereika SM, Bender CM, Brufsky AM, et al
    Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer.
    Cancer. 2017 Feb 15. doi: 10.1002/cncr.30575.
    PubMed     Text format     Abstract available


  57. BARCENAS CH, Raghavendra A, Sinha AK, Syed MP, et al
    Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
    Cancer. 2017 Feb 15. doi: 10.1002/cncr.30618.
    PubMed     Text format     Abstract available


  58. PEPPERCORN J, Horick N, Houck K, Rabin J, et al
    Impact of the elimination of cost sharing for mammographic breast cancer screening among rural US women: A natural experiment.
    Cancer. 2017 Feb 14. doi: 10.1002/cncr.30629.
    PubMed     Text format     Abstract available


  59. SADIM M, Xu Y, Selig K, Paulus J, et al
    Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer.
    Cancer. 2017 Feb 14. doi: 10.1002/cncr.30628.
    PubMed     Text format     Abstract available


  60. DONALDSON AR, Shetty S, Wang Z, Rivera CL, et al
    Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Cancer. 2017 Feb 13. doi: 10.1002/cncr.30592.
    PubMed     Text format     Abstract available


  61. MILLER JA, Kotecha R, Ahluwalia MS, Mohammadi AM, et al
    Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
    Cancer. 2017 Feb 13. doi: 10.1002/cncr.30616.
    PubMed     Text format     Abstract available


  62. CRAGUN D, Weidner A, Lewis C, Bonner D, et al
    Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
    Cancer. 2017 Feb 9. doi: 10.1002/cncr.30621.
    PubMed     Text format     Abstract available


  63. MANYAM BV, Garsa AA, Chin RI, Reddy CA, et al
    A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck.
    Cancer. 2017 Feb 7. doi: 10.1002/cncr.30601.
    PubMed     Text format     Abstract available


  64. SAAB J, Hoda RS, Narula N, Hoda SA, et al
    Diagnostic yield of cytopathology in evaluating pericardial effusions: Clinicopathologic analysis of 419 specimens.
    Cancer. 2017;125:128-137.
    PubMed     Text format     Abstract available


  65. WANG H, Hoda RS, Faquin W, Rossi ED, et al
    FNA biopsy of secondary nonlymphomatous malignancies in salivary glands: A multi-institutional study of 184 cases.
    Cancer. 2017;125:91-103.
    PubMed     Text format     Abstract available


  66. SPRING LM, Marshall MR, Warner ET
    Mammography decision making: Trends and predictors of provider communication in the Health Information National Trends Survey, 2011 to 2014.
    Cancer. 2017;123:401-409.
    PubMed     Text format     Abstract available


  67. WANG EH, Park HS, Rutter CE, Gross CP, et al
    Association between access to accelerated partial breast irradiation and use of adjuvant radiotherapy.
    Cancer. 2017;123:502-511.
    PubMed     Text format     Abstract available


    January 2017
  68. RAGHAVENDRA A, Sinha AK, Le-Petross HT, Garg N, et al
    Mammographic breast density is associated with the development of contralateral breast cancer.
    Cancer. 2017 Jan 30. doi: 10.1002/cncr.30573.
    PubMed     Text format     Abstract available


  69. FRIESE CR, Harrison JM, Janz NK, Jagsi R, et al
    Treatment-associated toxicities reported by patients with early-stage invasive breast cancer.
    Cancer. 2017 Jan 24. doi: 10.1002/cncr.30547.
    PubMed     Text format     Abstract available


  70. BUYS SS, Sandbach JF, Gammon A, Patel G, et al
    A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Cancer. 2017 Jan 13. doi: 10.1002/cncr.30498.
    PubMed     Text format     Abstract available


  71. WATANABE T, Kuranami M, Inoue K, Masuda N, et al
    Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 stu
    Cancer. 2017 Jan 12. doi: 10.1002/cncr.30421.
    PubMed     Text format     Abstract available


  72. MORTIMER JE, Waliany S, Dieli-Conwright CM, Patel SK, et al
    Objective physical and mental markers of self-reported fatigue in women undergoing (neo)adjuvant chemotherapy for early-stage breast cancer.
    Cancer. 2017 Jan 6. doi: 10.1002/cncr.30426.
    PubMed     Text format     Abstract available


  73. LICHTENTHAL WG, Corner GW, Slivjak ET, Roberts KE, et al
    A pilot randomized controlled trial of cognitive bias modification to reduce fear of breast cancer recurrence.
    Cancer. 2017 Jan 5. doi: 10.1002/cncr.30478.
    PubMed     Text format     Abstract available


  74. PATEL TA, Puppala M, Ogunti RO, Ensor JE, et al
    Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods.
    Cancer. 2017;123:114-121.
    PubMed     Text format     Abstract available


  75. WEN HY, Krystel-Whittemore M, Patil S, Pareja F, et al
    Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.
    Cancer. 2017;123:131-137.
    PubMed     Text format     Abstract available


  76. SILVESTRI V, Zelli V, Valentini V, Rizzolo P, et al
    Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
    Cancer. 2017;123:210-218.
    PubMed     Text format     Abstract available


    December 2016
  77. HOU JY, Baptiste C, Hombalegowda RB, Tergas AI, et al
    Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma.
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30473.
    PubMed     Text format     Abstract available


  78. VAPIWALA N, Hwang WT, Kushner CJ, Schnall MD, et al
    No impact of breast magnetic resonance imaging on 15-year outcomes in patients with ductal carcinoma in situ or early-stage invasive breast cancer managed with breast conservation therapy.
    Cancer. 2016 Dec 16. doi: 10.1002/cncr.30479.
    PubMed     Text format     Abstract available


  79. KIM DW, Haydu LE, Joon AY, Bassett RL Jr, et al
    Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients.
    Cancer. 2016 Dec 2. doi: 10.1002/cncr.30463.
    PubMed     Text format     Abstract available


  80. YILMAZ AS, Ozer HG, Gillespie JL, Allain DC, et al
    Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors.
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30459.
    PubMed     Text format     Abstract available


    November 2016
  81. SNEIGE N, Hess KR, Multani AS, Gong Y, et al
    Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.
    Cancer. 2016 Nov 28. doi: 10.1002/cncr.30460.
    PubMed     Text format     Abstract available


  82. YEN TW, Pezzin LE, Li J, Sparapani R, et al
    Effect of hospital volume on processes of breast cancer care: A National Cancer Data Base study.
    Cancer. 2016 Nov 8. doi: 10.1002/cncr.30413.
    PubMed     Text format     Abstract available


    October 2016
  83. FRIESE CR, Li Y, Bondarenko I, Hofer TP, et al
    Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.
    Cancer. 2016 Oct 24. doi: 10.1002/cncr.30324.
    PubMed     Text format     Abstract available


  84. CLARKE LE, Flake DD 2nd, Busam K, Cockerell C, et al
    An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.
    Cancer. 2016 Oct 21. doi: 10.1002/cncr.30385.
    PubMed     Text format     Abstract available


  85. KOLLER PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, et al
    Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
    Cancer. 2016 Oct 20. doi: 10.1002/cncr.30362.
    PubMed     Text format     Abstract available


  86. GOODWIN EA, Burhansstipanov L, Dignan M, Jones KL, et al
    The experience of treatment barriers and their influence on quality of life in American Indian/Alaska Native breast cancer survivors.
    Cancer. 2016 Oct 20. doi: 10.1002/cncr.30406.
    PubMed     Text format     Abstract available


  87. BRAND JS, Hedayati E, Bhoo-Pathy N, Bergh J, et al
    Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study.
    Cancer. 2016 Oct 11. doi: 10.1002/cncr.30364.
    PubMed     Text format     Abstract available


    September 2016
  88. NYANTE SJ, Lee SS, Benefield TS, Hoots TN, et al
    The association between mammographic calcifications and breast cancer prognostic factors in a population-based registry cohort.
    Cancer. 2016 Sep 28. doi: 10.1002/cncr.30281.
    PubMed     Text format     Abstract available


  89. RAO R, Rivers A, Rahimi A, Wooldridge R, et al
    Genetic Ancestry using Mitochondrial DNA in patients with Triple-negative breast cancer (GAMiT study).
    Cancer. 2016 Sep 1. doi: 10.1002/cncr.30267.
    PubMed     Text format     Abstract available


    August 2016
  90. BRIER MJ, Chambless DL, Gross R, Chen J, et al
    Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
    Cancer. 2016 Aug 29. doi: 10.1002/cncr.30318.
    PubMed     Text format     Abstract available


  91. BHATIA S, Margolin K
    Disparate clinical activity of PD-1 blockade in melanoma subtypes: Know thy enemy!
    Cancer. 2016 Aug 17. doi: 10.1002/cncr.30260.
    PubMed     Text format    


  92. SHOUSHTARI AN, Munhoz RR, Kuk D, Ott PA, et al
    The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
    Cancer. 2016 Aug 17. doi: 10.1002/cncr.30259.
    PubMed     Text format     Abstract available


  93. ALGAZI AP, Tsai KK, Shoushtari AN, Munhoz RR, et al
    Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-1L antibodies.
    Cancer. 2016 Aug 17. doi: 10.1002/cncr.30258.
    PubMed     Text format     Abstract available


  94. JHAWAR SR, Kaufman HL, Goyal S
    Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Cancer. 2016 Aug 6. doi: 10.1002/cncr.30244.
    PubMed     Text format    


  95. YU JB, Chiang VL
    Reply to timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Cancer. 2016 Aug 6. doi: 10.1002/cncr.30243.
    PubMed     Text format    


    July 2016
  96. FERRERO JM, Hardy-Bessard AC, Capitain O, Lortholary A, et al
    Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
    Cancer. 2016 Jul 14. doi: 10.1002/cncr.30170.
    PubMed     Text format     Abstract available


  97. CURIEL-LEWANDROWSKI C, Swetter SM
    Lack of harms from community-based melanoma screening by primary care providers.
    Cancer. 2016 Jul 8. doi: 10.1002/cncr.30194.
    PubMed     Text format    


  98. WEINSTOCK MA, Ferris LK, Saul MI, Geller AC, et al
    Downstream consequences of melanoma screening in a community practice setting: First results.
    Cancer. 2016 Jul 8. doi: 10.1002/cncr.30177.
    PubMed     Text format     Abstract available


    June 2016
  99. DEGNIM AC, Dupont WD, Radisky DC, Vierkant RA, et al
    Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30153.
    PubMed     Text format     Abstract available


  100. OWUSU C, Margevicius S, Schluchter M, Koroukian SM, et al
    Vulnerable elders survey and socioeconomic status predict functional decline and death among older women with newly diagnosed nonmetastatic breast cancer.
    Cancer. 2016 Jun 27. doi: 10.1002/cncr.30046.
    PubMed     Text format     Abstract available


  101. GALIANO-CASTILLO N, Cantarero-Villanueva I, Fernandez-Lao C, Ariza-Garcia A, et al
    Telehealth system: A randomized controlled trial evaluating the impact of an internet-based exercise intervention on quality of life, pain, muscle strength, and fatigue in breast cancer survivors.
    Cancer. 2016 Jun 22. doi: 10.1002/cncr.30172.
    PubMed     Text format     Abstract available


  102. EATON BR, Jiang R, Torres MA, Kahn ST, et al
    Benefit of adjuvant radiotherapy after breast-conserving therapy among elderly women with T1-T2N0 estrogen receptor-negative breast cancer.
    Cancer. 2016 Jun 21. doi: 10.1002/cncr.30142.
    PubMed     Text format     Abstract available


  103. LEREBOURS F, Rivera S, Mouret-Reynier MA, Alran S, et al
    Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French t
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30143.
    PubMed     Text format     Abstract available


  104. DROOGER JC, van Tinteren H, de Groot SM, Ten Tije AJ, et al
    A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30141.
    PubMed     Text format     Abstract available


  105. BJURSTAM NG, Bjorneld LM, Duffy SW
    Updated results of the Gothenburg Trial of Mammographic Screening.
    Cancer. 2016;122:1832-5.
    PubMed     Text format     Abstract available


  106. GUINDALINI RS, Song A, Fackenthal JD, Olopade OI, et al
    Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect.
    Cancer. 2016;122:1913-20.
    PubMed     Text format     Abstract available


  107. QIAN JM, Yu JB, Kluger HM, Chiang VL, et al
    Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Cancer. 2016 Jun 10. doi: 10.1002/cncr.30138.
    PubMed     Text format     Abstract available


  108. ROSS JS, Gay LM, Wang K, Ali SM, et al
    Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Cancer. 2016 Jun 10. doi: 10.1002/cncr.30102.
    PubMed     Text format     Abstract available


    May 2016
  109. DIELI-CONWRIGHT CM, Wong L, Waliany S, Bernstein L, et al
    An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy.
    Cancer. 2016 May 24. doi: 10.1002/cncr.30104.
    PubMed     Text format     Abstract available


  110. GIESE-DAVIS J, Bliss-Isberg C, Wittenberg L, White J, et al
    Peer-counseling for women newly diagnosed with breast cancer: A randomized community/research collaboration trial.
    Cancer. 2016 May 19. doi: 10.1002/cncr.30036.
    PubMed     Text format     Abstract available


  111. GUO X, Cai Q, Bao P, Wu J, et al
    Long-term soy consumption and tumor tissue MicroRNA and gene expression in triple-negative breast cancer.
    Cancer. 2016 May 16. doi: 10.1002/cncr.29981.
    PubMed     Text format     Abstract available


  112. VERMA V, Mishra MV, Mehta MP
    A systematic review of the cost and cost-effectiveness studies of proton radiotherapy.
    Cancer. 2016;122:1483-501.
    PubMed     Text format     Abstract available


  113. BRADLEY MC, Black A, Freedman AN, Barron TI, et al
    Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Cancer. 2016 May 3. doi: 10.1002/cncr.30004.
    PubMed     Text format     Abstract available


  114. FERGUSON RJ, Sigmon ST, Pritchard AJ, LaBrie SL, et al
    A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction.
    Cancer. 2016 May 2. doi: 10.1002/cncr.29891.
    PubMed     Text format     Abstract available


  115. PRINTZ C
    Delaying chemotherapy after surgery in patients with breast cancer reduces survival.
    Cancer. 2016;122:1311.
    PubMed     Text format    


    April 2016
  116. PRINTZ C
    BRCA 1/2-negative patients who receive counseling after genetic testing have lower anxiety.
    Cancer. 2016;122:1149.
    PubMed     Text format    


  117. DRILON A, Eaton AA, Schindler K, Gounder MM, et al
    Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
    Cancer. 2016;122:1228-37.
    PubMed     Text format     Abstract available


  118. SHAH PD, Patil S, Dickler MN, Offit K, et al
    Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.
    Cancer. 2016;122:1178-84.
    PubMed     Text format     Abstract available


  119. PRINTZ C
    Minority women more likely to develop aggressive breast cancer.
    Cancer. 2016;122:986-7.
    PubMed     Text format    


    March 2016
  120. PRINTZ C
    ACS updates breast cancer screening guidelines.
    Cancer. 2016;122:663.
    PubMed     Text format    


  121. PRINTZ C
    Developments in precision medicine: Studies highlight new applications for cancer chemoprevention, treatment.
    Cancer. 2016;122:661-2.
    PubMed     Text format    


  122. WRIGHT BJ, Conlin AK, Allen HL, Tsui J, et al
    What does Medicaid expansion mean for cancer screening and prevention? Results from a randomized trial on the impacts of acquiring Medicaid coverage.
    Cancer. 2016;122:791-7.
    PubMed     Text format     Abstract available


    February 2016
  123. ARMSTRONG K, Kim JJ, Halm EA, Ballard RM, et al
    Using lessons from breast, cervical, and colorectal cancer screening to inform the development of lung cancer screening programs.
    Cancer. 2016 Feb 29. doi: 10.1002/cncr.29937.
    PubMed     Text format     Abstract available


  124. HAAS JS, Hill DA, Wellman RD, Hubbard RA, et al
    Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status.
    Cancer. 2016;122:611-7.
    PubMed     Text format     Abstract available


  125. LIGIBEL JA, Giobbie-Hurder A, Shockro L, Campbell N, et al
    Randomized trial of a physical activity intervention in women with metastatic breast cancer.
    Cancer. 2016 Feb 12. doi: 10.1002/cncr.29899.
    PubMed     Text format     Abstract available



  126. Breast cancer incidence and death increasing in less-developed countries.
    Cancer. 2016;122:339.
    PubMed     Text format    



  127. Prenatal exposure to maternal cancer with or without treatment does not impair child development.
    Cancer. 2016;122:338-9.
    PubMed     Text format    



  128. Women at low risk for breast cancer recurrence can avoid chemotherapy: Initial trial findings support current practices.
    Cancer. 2016;122:337-338.
    PubMed     Text format    


  129. TEVAARWERK AJ, Lee JW, Terhaar A, Sesto ME, et al
    Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study.
    Cancer. 2016;122:438-46.
    PubMed     Text format     Abstract available


  130. STOVER AM, Basch EM
    Using patient-reported outcome measures as quality indicators in routine cancer care.
    Cancer. 2016;122:355-7.
    PubMed     Text format    


  131. SMITH TG, Castro KM, Troeschel AN, Arora NK, et al
    The rationale for patient-reported outcomes surveillance in cancer and a reproducible method for achieving it.
    Cancer. 2016;122:344-51.
    PubMed     Text format     Abstract available


  132. KAYMAKCALAN MD, Xie W, Albiges L, North SA, et al
    Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Ca
    Cancer. 2016;122:411-9.
    PubMed     Text format     Abstract available


  133. VISSCHER DW, Frost MH, Hartmann LC, Frank RD, et al
    Clinicopathologic features of breast cancers that develop in women with previous benign breast disease.
    Cancer. 2016;122:378-85.
    PubMed     Text format     Abstract available


    January 2016
  134. LAI JS, Beaumont JL, Diaz J, Khan S, et al
    Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.
    Cancer. 2016;122:287-95.
    PubMed     Text format     Abstract available


  135. BLEICHER RJ, Ruth K, Sigurdson ER, Daly JM, et al
    Breast conservation versus mastectomy for patients with T3 primary tumors (>5 cm): A review of 5685 medicare patients.
    Cancer. 2016;122:42-9.
    PubMed     Text format     Abstract available


    December 2015
  136. KUMACHEV A, Trudeau ME, Chan KK
    Associations among socioeconomic status, patterns of care and outcomes in breast cancer patients in a universal health care system: Ontario's experience.
    Cancer. 2015 Dec 22. doi: 10.1002/cncr.29838.
    PubMed     Text format     Abstract available


  137. HAHN EE, Tang T, Lee JS, Munoz-Plaza CE, et al
    Use of posttreatment imaging and biomarkers in survivors of early-stage breast cancer: Inappropriate surveillance or necessary care?
    Cancer. 2015 Dec 9. doi: 10.1002/cncr.29811.
    PubMed     Text format     Abstract available


  138. CHURPEK JE, Marquez R, Neistadt B, Claussen K, et al
    Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.
    Cancer. 2015 Dec 7. doi: 10.1002/cncr.29615.
    PubMed     Text format     Abstract available


    November 2015
  139. BURNSIDE ES, Drukker K, Li H, Bonaccio E, et al
    Using computer-extracted image phenotypes from tumors on breast magnetic resonance imaging to predict breast cancer pathologic stage.
    Cancer. 2015 Nov 30. doi: 10.1002/cncr.29791.
    PubMed     Text format     Abstract available


  140. COLLINS LC, Aroner SA, Connolly JL, Colditz GA, et al
    Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses' Health Studies.
    Cancer. 2015 Nov 13. doi: 10.1002/cncr.29775.
    PubMed     Text format     Abstract available


  141. NYROP KA, Deal AM, Williams GR, Guerard EJ, et al
    Physical activity communication between oncology providers and patients with early-stage breast, colon, or prostate cancer.
    Cancer. 2015 Nov 13. doi: 10.1002/cncr.29786.
    PubMed     Text format     Abstract available


  142. HASSETT MJ, Schymura MJ, Chen K, Boscoe FP, et al
    Variation in breast cancer care quality in New York and California based on race/ethnicity and Medicaid enrollment.
    Cancer. 2015 Nov 4. doi: 10.1002/cncr.29777.
    PubMed     Text format     Abstract available


    October 2015
  143. FROES BRANDAO D, Strasser-Weippl K, Goss PE
    Prolactin and breast cancer: The need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: A review.
    Cancer. 2015 Oct 12. doi: 10.1002/cncr.29714.
    PubMed     Text format     Abstract available


    March 2015
  144. UNGER-SALDANA K, Miranda A, Zarco-Espinosa G, Mainero-Ratchelous F, et al
    Health system delay and its effect on clinical stage of breast cancer: Multicenter study.
    Cancer. 2015 Mar 24. doi: 10.1002/cncr.29331.
    PubMed     Text format     Abstract available


  145. KHANKARI NK, Bradshaw PT, Steck SE, He K, et al
    Dietary intake of fish, polyunsaturated fatty acids, and survival after breast cancer: A population-based follow-up study on Long Island, New York.
    Cancer. 2015 Mar 24. doi: 10.1002/cncr.29329.
    PubMed     Text format     Abstract available


  146. SIGHOKO D, Ogundiran T, Ademola A, Adebamowo C, et al
    Breast cancer risk after full-term pregnancies among African women from Nigeria, Cameroon, and Uganda.
    Cancer. 2015 Mar 17. doi: 10.1002/cncr.29305.
    PubMed     Text format     Abstract available


  147. CHLEBOWSKI RT, Schottinger JE, Shi J, Chung J, et al
    Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
    Cancer. 2015 Mar 10. doi: 10.1002/cncr.29332.
    PubMed     Text format     Abstract available


  148. CRAMER H, Rabsilber S, Lauche R, Kummel S, et al
    Yoga and meditation for menopausal symptoms in breast cancer survivors-A randomized controlled trial.
    Cancer. 2015 Mar 4. doi: 10.1002/cncr.29330.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: